ideasIdea
Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes
Radioactive cancer drugs decay while they travel and get stuck at borders. Regional production and simpler transport rules would get more doses to patients on time.
Radioligand therapies are often labelled centrally and shipped internationally, losing activity to decay and to customs delays; dangerous goods rules differ by country and carrier. The proposal is a network of regional GMP radiopharmacies (one per few million population) receiving bulk isotope and cold kits, labelling on demand, and delivering same-day, combined with an IAEA-brokered harmonisation of Class 7 transport paperwork and pre-clearance for medical isotopes at major airports.
Hypothesis
Regional labelling and pre-clearance reduce the share of radioligand doses cancelled or postponed for supply reasons from roughly 5-10% to below 1% and reduce shipped activity per delivered dose by at least a quarter.
Rationale
Nuclear medicine already runs this way for diagnostic isotopes (technetium generators, fluorine-18 cyclotron networks). Therapeutic isotopes have longer half-lives but far higher per-dose value, so the economics of regional hubs are favourable.
What would test it
Pilot two regional hubs in a large country and measure dose cancellation rates, shipped activity per dose and cost per dose against central supply over one year.
Maturity
early clinical
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.